ARCH invests primarily in companies co-founded by scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences. They enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories. ARCH has raised ten venture funds totaling over $3 billion and has invested in the venture capital rounds for more than 150 companies. ARCH investors include corporations, pension funds, endowment funds, financial institutions, and private investors.

ARCH Venture Partners

Cortado Ventures invest in capital-efficient businesses that leverage technology to scale in the fintech, biotech, aerospace, ag tech, and energy tech.  It was founded in 2020 and headquartered in Oklahoma, United States. Intake form: https://cortado.ventures/contact-us/

Cortado Ventures

OLSF I is invested in five start-ups that have created over 100 jobs with a mean income that is three times greater than the state average. These companies have attracted over $210 million in venture capital from regional and national venture capital firms after OLSF's first investment.

Oklahoma Life Science Fund

Sage Venture Partners invests in early and gowth-stage startups across diverse industries. Sage Venture Partners typically invests with a close group of family offices and individuals and provides extensive guidance and management to portfolio companies. The firm backs entrepreneurs with proven track records and strong strategic vision.    Sage Venture Partners is founded and led by Frederick J. Warren. Before Sage Venture Partners, Mr. Warren co-founded Brentwood Associates, which became a leading venture capital investment firm on the West Coast. In 1984, he initiated and led Brentwood's formal entry into the leveraged buyout business and its evolution as a private equity investment firm.

Sage Venture Partners

Early stage, technology venture capital fund

1843 Capital

DeepWork Capital, a Florida-based venture capital firm, invests in high-growth early-stage companies in the technology and life science sectors through proprietary and public committed capital funds. The Firm partners with visionary entrepreneurs building world-changing companies and supports portfolio companies' successes with active engagement.  For additional information, please see https://www.deepworkcapital.com.

DeepWork Capital

The Flippen Group is a management consulting firm based in Texas.

The Flippen Group

4D Capital is a venture capital, private equity, and commercial real estate investment firm based in the United States. As founders turned investors, we understand the pre-IPO landscape from every angle. We play an active role in the companies we invest in, leveraging our entrepreneurial, go-to-market, and stage expertise, as well as our network of industry experts.

4D Capital

Recuro Health

Recuro Health delivers value throughout the healthcare ecosystem with an integrated digital health solution that transitions the U.S. healthcare system from a reactive, disease-focused model to a population health, outcomes approach. Digital Medical Home can be tailored to specific healthcare requirements. They offer fundamental virtual care services such as primary care, behavioral health, and urgent care.

<div>Recuro Health is a general telemedicine startup and integrated virtual care provider that was launched in March 2021 by the founding CEO of Teladoc. The company plans to provide an end-to-end solution comprising a range of primary care services, remote lab testing, behavioral health consultations, remote patient monitoring, and care coordination services to healthcare providers, employers, and payers via the integrated digital platform.</div>

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

<div>
 
 Recuro Health is a general telemedicine startup and integrated virtual care provider that was launched in March 2021 by the founding CEO of Teladoc. The company plans to provide an end-to-end solution comprising a range of primary care services, remote lab testing, behavioral health consultations, remote patient monitoring, and care coordination services to healthcare providers, employers, and payers via the integrated digital platform.
 
 
 Key customers and partnerships
 
 
 In August 2022, the 
 <a href="https://sp-edge.com/updates/12555">
 company acquired
 </a>
 integrated digital health solutions provider Competitive Health for an undisclosed sum. The acquisition will help Recuro Health expand its integrated benefits service offerings available on its Digital Medical Home platform and to increase its market reach. 
 
 
 Funding and financials
 
 
 In April 2023, the company raised USD 47 million in a Series B funding round which had participation from several venture capital firms, including new and existing investors. The raised funds were set aside to advance and scale its &ldquo;Digital Medical Home&rdquo; solution, along with growing the company and expanding its market reach. 
 
</div>

<div>
 
 Nice Healthcare is a US based telehealth company with a focus on primary care services to business-to-business (B2B) clients. Once the employer signs its employees with Nice (at a cost of USD 30 to USD 36 per employee per month), employees do not have to incur out of pocket expenses for Nice services and can schedule virtual or home visits within the time frames specified by the company. It connects patients with practitioners through a mobile app over video calls or text messages. Members can also request home visits which will be completed within a few hours, as claimed by the company. As of March 2022, Nice was operating in twelve states, and had over 400 small and medium enterprises (SMEs).
 
 
 In March 2022, the company raised USD 30 million in Series A financing led by DNA Capital which has been earmarked to expand its platform&rsquo;s reach among small and medium businesses. Additionally, the company is hiring three members for its management team to support the continuing growth of the organization.
 
 
 
</div>

Nice Healthcare

<div>
 
 Amicomed is a cloud-based Software-as-a-Service (SaaS) platform which provides blood pressure monitoring services. It collects blood pressure data of patients from at-home devices, applies algorithms, and assesses the fluctuations in the blood pressure. Physicians can be connected and provided with blood pressure data of their patients in order to facilitate their workload, enabling more personalized management of patients regarding medication and lifestyle indications. 
 
 
 Amicomed can also recommend actionable and personalized lifestyle interventions such as daily diet and exercises via virtual coaching.
 
</div>

Amicomed

<div>
 
 Winston is a men&rsquo;s health telemedicine platform that treats common issues impacting men such as sexual problems, hair loss, acne, and cold sores. Winston allows patients to consult doctors, place orders for prescription drugs, and offers free delivery to the homes of patients. 
 
 
 The Toronto-based company aims to avoid men deferring doctor visits or withholding sensitive information. The consultation fee is covered by the provincial health plan, but the prescriptions are billed to the customer.
 
</div>

Winston

<div>
 
 Eko Health is a cardiopulmonary digital health company that aims to improve heart and lung care for patients using sensors and artificial intelligence. The company produces connected handheld digital stethoscopes with electrocardiogram functionality to detect heart rhythm abnormalities using artificial intelligence (AI) algorithms. In 2020, the company obtained 501(k) FDA clearance for multiple algorithms that help detect heart murmurs and atrial fibrillation, or AFib. These algorithms were used in 2022 to develop the Eko App, which pairs to the company's stethoscopes for report generation, information sharing and carrying out examinations. 
 
 
 The company operates on a fee per unit B2B2C model and a D2C model, where it provides its technology to medical practitioners or patients for diagnostic purposes.
 
 
 In February 2023, Eko 
 <a href="https://sp-edge.com/updates/16677">
 launched SENSORA
 </a>
 , a cardiac disease detection platform that combines the company&rsquo;s existing digital stethoscopes with a machine learning-based platform. The platform enables primary care physicians to detect structural murmurs and assess heart arrhythmias by using a database of heart sounds to compare and identify anomalies in a patient's heart beat. 
 
 
 In April 2024, Eko 
 <a href="https://sp-edge.com/updates/28111">
 obtained FDA 510(k) clearance
 </a>
 for its AI-aided cardiac tool, Eko Low Ejection Fraction Tool (ELEFT). The tool is designed to assist providers in early detection of low ejection fraction, a significant sign of heart failure.
 
 
 Funding and financials
 
 
 In March 2022, raised a further USD 30 million in an extension to its Series C round, which began November 2020. The total funds raised by the company stood at USD 126 million as of March. These funds have been allocated to support further commercialization efforts and develop new products for the company.
 
 
 
 
 
 
 
</div>

<div>
 
 Dialogue partners with employers and health insurers to offer telehealth services to their employees and members. The users have 24/7 access to doctors, nurses, and other healthcare professionals via audio, video, and chat options for wide arrays of physical and mental health needs, artificial intelligence-enabled (AI-enabled) triage, referrals, and prescription renewals. 
 
 
 The company launched its trademarked Integrated Health Platform in January 2021 to consolidate its virtual care, wellness programs, mental healthcare services, and Employee Assistance Program (EAP) onto a single platform. The company claims to be the only integrated health and wellness B2B platform in Canada. 
 
 
 Key Customers and partnerships
 
 
 Dialogue had direct relationships with over 2,000 customers across Canada and Germany as of December 2020 and served around 50,000 organizations through these partnerships. In addition, the number of members with access to the virtual platform topped 1 million in January 2021. 
 
 
 Fundings and financials
 
 
 As of March 2021, Dialogue was planning to raise CAD 100 million (USD 80 million) from an initial public offering that will be listed on the Toronto Stock Exchange under the ticker symbol &ldquo;CARE.&rdquo; 
 
 
 In Q2 2023, net losses reduced significantly YoY to CAD 5.8 million (USD 4.3 million) from CAD 8.4 million (USD 6.3 million) in Q2 2022. Top-line revenue met internal expectations, growing 17.2% YoY to CAD 25.5 million (USD 19.0 million), driven by &nbsp;an increase in new members (by 18.6% YoY), 
 an expansion of the attach rate as existing customers added more services, and full-quarter contributions from Tictrac.
 
 Dialogue Health has not provided any forward-looking guidance as the company has entered into an agreement to be 
 <a href="https://investors.dialogue.co/English/news/news-details/2023/Dialogue-to-be-Acquired-by-Sun-Life/default.aspx">
 acquired by financial services company Sun Life Financial
 </a>
 for a consideration of CAD 365 million (USD 270 million) or CAD 5.15 (USD 3.82) per share. The transaction is expected to close in Q4 2023. Post acquisition, Dialogue will delist from the Toronto Stock Exchange but will continue to operate as a standalone entity under the &ldquo;Sun Life Canada&rdquo; brand from its head office in Qu&eacute;bec. 
 
 
 
</div>

Dialogue

IoT is used by most telehealth providers to operate virtual services

All telehealth players are involved in digital health via virtual offerings

Industry players offer varying degrees of personalization for each target audience

Some players offer technology and platforms to healthcare providers, converting physical-only services into virtual services

Specific telehealth offerings focus on diversity and inclusion, providing care to LGBTQ+ or BIPOC populations

Generative AI is used to streamline administrative tasks such as clinical note-taking

Primary care through virtual consultations for general health-related concerns using a digital platform or mobile app. 

Recuro Health

Telehealth

Key stats

Recent Updates

Recuro Health appoints Phil Fasano as chairman and CEO

Recuro Health raises USD 47 million in Series B funding

Recuro Health acquires Competitive Health to expand service offerings and market reach

Recuro Health raises USD 15 million in Series A funding

Company Brief

Funding

Investors

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless